<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates — Live Feed</title><link>https://www.live-feeds.com/feed/eli-lilly-leads-5-stocks-near-buy-points-as-the-market-rally-rotates</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/eli-lilly-leads-5-stocks-near-buy-points-as-the-market-rally-rotates/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Eli Lilly Shares Rise on EU Panel Support for Jaypirca</title><link>https://www.live-feeds.com/feed/eli-lilly-leads-5-stocks-near-buy-points-as-the-market-rally-rotates</link><guid isPermaLink="false">https://www.live-feeds.com/feed/eli-lilly-leads-5-stocks-near-buy-points-as-the-market-rally-rotates#u23809</guid><pubDate>Sat, 04 Jul 2026 04:11:41 +0000</pubDate><description>Eli Lilly stock reached a new all-time high following an EU panel recommendation for expanded use of Jaypirca. The company is among several stocks near buy points as the market rally shifts toward healthcare. Shares rose up to 10.0% following the EU nod and GLP-1 access developments.What's confirmed:An EU panel backed the expanded use of Jaypirca.The Committee for Medicinal Products for Human Use met from 22-25 June 2026.Eli Lilly stock reached a new all-time high.Still unconfirmed:Eli Lilly stock rose 10.0% after an EU CLL nod and GLP-1 access win.Eli Lilly gained 7% on Friday.Eli Lilly share</description></item>
</channel></rss>